Please keep reading our information because it changes every day. Below is the latest information provided to the association -- please note that we will continue to send updates as soon as we receive any new information.
Monday, November 9, 2020
AHCA Reminds Us to Continue Posting Daily to ESS
With Tropical Storm Eta still looming over south Florida, and another system that is expected to form in the Atlantic this week that could become Tropical Storm Theta, AHCA is paying close attention to the recent postings in the Emergency Status System (ESS).

AHCA has noticed that several communities have reported the same numbers for positive staff for the past three or four weeks. They are asking communities to only post the numbers of active positive staff, not a cumulative total of all positive staff.

They are also reminding everyone that until there is an end to any COVID spread in communities, they will continue to require everyone to post to ESS on a daily basis by 10:00 a.m.

If for any reason you are not able to post to ESS, please let us know at

Also, if there is anything we can do to help you during the storm, please do not hesitate to reach out. We are always here to help!!
If You Did Not Register for Vaccine Program, It's Not Too Late -- Please Let Us Know ASAP

At this Time, CVS and Walgreens are the only two Pharmacies Participating in this Program

Florida's Department of Health is working to make sure that all assisted living providers have signed up for the on-site COVID-19 vaccination services for residents (and staff) of nursing homes and assisted living facilities.

If you did not register, please send an email to FSLA at and we will work with DOH to get you signed up.
Pfizer and BioNTech Release Vaccine Early Look

Pfizer and German mRNA biotech partner BioNTech have released an early look at their experimental pandemic vaccine, and the news is good.

The pair’s mRNA-based vaccine candidate, BNT162b2, has shown in its closely watched phase 3 that it was more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis.

This is a big deal, given that most saw 50% to 70% effectiveness as a strong win; 90% is likely the best case for the vaccine, and Pfizer cautioned that as more data come in, this could change. The data are based on a two-shot dosing schedule, and the 90% figure comes 28 days after the initial dose.